

RNS Number : 9944M  
Quantum Pharma PLC  
19 October 2016

19 October 2016

This announcement contains inside information

Quantum Pharma Plc

('Quantum', the 'Group' or the 'Company')

CEO appointment and Board Changes

Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces the following changes and proposed changes to its board of directors (the 'Board').

Following a formal search process, and having taken into account the feedback of a number of Quantum's major shareholders who are fully supportive of the strategy to simplify and focus the Group, the Board has today appointed Chris Rigg to the position of Chief Executive Officer ("CEO") on a permanent basis. Chris was appointed to the Board as Chief Financial Officer ("CFO") in March 2016 and has been Acting CEO since 1 August 2016. The Board has commenced a formal search process for a new CFO but, in the interim, as well as permanent CEO, Chris will remain as CFO until a replacement for that role is appointed.

Quantum is also pleased to announce the appointments to the Board of Ian Johnson as non-executive Chairman; Christopher Mills as non-executive Director and Dr John Brown as Senior Independent non-executive Director. The Board has commenced a formal search process for a further non-executive Director. John Clarke and Sheila Kelly, non-executive Chairman and non-executive Director respectively, have resigned from their positions on the Board with immediate effect to focus on other Directorships and new business appointments.

Ian Johnson is an experienced director in the healthcare and life science sector. He was founder and CEO of Biotrace International plc until its sale to 3M in 2006 and is currently Executive Chairman of Bioquell PLC and non-executive Chairman of Cyprotex plc. Ian has also served on the boards of various public and private companies in strategic consultancy and business development capacities including: Celsis International, Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc. Ian is a chartered biologist and a member of the Royal Society of Biology and the Institute of Directors.

Christopher Mills is an experienced non-executive Director. He founded Harwood Capital Management Ltd in 2011, a successor from its former parent company J O Hambro Capital Management Ltd, which he co-founded in 1993. He is Chief Executive of North Atlantic Smaller Companies Investment Trust plc, a Director and Investment Manager of Oryx International Growth Fund Ltd and Chief Investment Officer of Harwood Capital LLP. He is also a non-executive Director of several AIM-listed companies. Christopher was a Director of Invesco MIM, where he was head of North American investments and venture capital and of Samuel Montagu International. Together, North Atlantic Smaller Companies Investment Trust PLC and Oryx International Growth Fund Limited are interested in 13,850,000 Ordinary Shares representing 11.08 per cent. of the entire issued share capital of the Company.

Dr John Brown is an experienced non-executive director who has extensive experience in the life sciences and healthcare sectors. He is Chairman of Kyowa Kirin International and the Cell and Gene Therapy Catapult and a Director of Electrical Geodesics Inc. His board experience includes his roles as Chairman of Touch Bionics Ltd, BTG plc, and Axis-Shield plc, and as a Director of Vectura Group plc, Cambridge Antibody plc and Acambis plc.

Chris Rigg, Quantum's CEO & CFO, said:

"I am delighted to be appointed as Quantum's CEO and would like to thank the Board and our major shareholders for their support. Whilst the Group has faced some challenges in the recent past, the focused and simplified strategy now in place has the potential to drive shareholder value and I look forward to working with Ian, Christopher, John and Quantum's senior management team to deliver this.

"On behalf of Quantum, I would also like to thank John Clarke and Sheila Kelly for their services since the Group's admission to AIM in 2014 and wish them well for the future."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules

for Companies. Ian Roy Johnson, age 63 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships	Past directorships
Biofortuna Limited	Celesis Group Limited
Bioquell Plc	Finance Wales Plc
Bioquell UK Limited	Lumora Limited
Bioxyquell Limited	Mycelx Technologies Corporation
Cyprotex plc	Ruskinn Life Sciences Limited
Klenitise Limited	Toximent Limited

Companies that went into administration and creditors lost money as a result of liquidation:

- Pure Options Solutions - Administrators appointed on 30 November 2010. The estimated deficiency to investors and creditors was £4.49 million.

Administration ongoing:

- Toximet Limited - Ian Johnson resigned on 30 April 2015 - Administrator appointed 13 November 2015.

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. John Robert Brown, age 61 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships	Past directorships
BioCity Nottingham Ltd	Axis-Shield plc Touch Bionics Ltd
Cell Therapy Catapult Ltd	BioIndustry Association
Electrical Geodesic Inc	CXR Ltd
ProStrakan Group Ltd	Mode Diagnostics Ltd
Synpromics Ltd	Scottish LifeSciences Association
	Vectura Group plc

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Christopher Harwood Bernard Mills, age 63 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships	Past directorships
62 Pont Street (Freehold) Limited	Academic Research Ltd

Agrisense Industrial Monitoring Limited	Alba Investment Properties Intermediate Holdings Limited
Alba Investment Properties Holdings Limited	Baltimore Capital PLC (in liquidation)
Alba Investment Properties Limited	Baltimore Technologies (Holdings) Limited
Alternatport Limited	Baltimore Technologies (UK) Limited
Assetco PLC	Bionostics Holdings Ltd
B&G (Europe) Holding Limited	Bionostics Ltd
B&G Equipment Co	CCH Advisers Ltd
Bioquell PLC	Celsis Group Ltd
Catalyst Media Group PLC	Celsis International Ltd
Catalyst Media Holdings Limited	Darby Group Limited
Consolidated Venture Finance Limited	Forefront Group Ltd
Coventbridge Group Limited	GTL Resources Ltd
Cross-Border Publishing (London) Limited	GTL Resources Overseas Investments Ltd
Cyprotex PLC	H.Townsend & Sons (Builders) Limited
EKF Diagnostics Holdings PLC	Hampton Land & Estates Limited
GlobalOptions Group, Inc.	Hampton Trust PLC
Goals Soccer Centres PLC	Harwood Capita LLP
Growth Financial Services Limited	Highrix Limited
Hampton Investment Properties Limited	Izodia Plc
Harwood Capital Management Limited	J O Hambro Capital Management Ltd
Harwood Capital Nominees Limited	Jarvis Porter (Property Holdings Ltd)
Harwood Holdco Limited	Kelvinhaugh Student accommodation Limited
Harwood Multi Manager Limited	M J Gleeson Ltd
Harwood Real Estate Limited	Merchant Properties General Partner Ltd
Harwood Wealth Management Group PLC	Merchant Properties Nominees Ltd
Indoor Bowling Acquisitions Limited	Merchant Properties Two General Partner Ltd
Indoor Bowling Equity Limited	Merchant Properties Two Nominee 1 Ltd
IR Media Group Limited	Merchant Properties Two Nominee 2 Ltd
Jaguar Holdings Limited	Mount Street Properties Limited
Journey Group PLC	Nastor Investments Ltd
MJ Gleeson PLC	Nationwide Accident Repair Services Ltd
North Atlantic Smaller Companies Investment Trust PLC	Orthoproducts Ltd
Oryx International Growth Fund Limited	Prime Focus London PLC
Performance Chemicals Company	Progeny, Inc.
Satellite Information Services (Holdings) Limited	Quarto Group Inc.
Sherwood Holdings Limited	RGS(1) Ltd
Source Bioscience Plc	Sinav Ltd
Stratton Street (Anthony) Limited	Stratifer Ltd
Stratton Street (Mouse No.1) Limited	Toftplan Property Ltd
Sunlink Health Systems, Inc.	Valient Sports Holdings Ltd
Team Rock Limited	W G Mitchell (2005) Ltd
The Indoor Bowling Company	W G Mitchell (Charlotte Square) Ltd
The Tagos Group	W G Mitchell (Fifteen) Ltd
Tramworks Limited (in liquidation)	W G Mitchell (George Street) Ltd
	W G Mitchell (Seven) Ltd
	W G Mitchell Enterprises Ltd
	Winnfield Holding Corporation

In addition, Christopher Mills has been a director of the following companies which have been placed into liquidation or receivership/administration:

All creditors paid in full:

- Nationwide Security Group plc - Receivership completed 2 March 2005
- Tricor plc - resigned 3 February 2003 - Voluntary arrangement completed 2 April 2014

Companies that went into administration and creditors lost money as a result of liquidation:

- Valiant Sports Holdings Limited - Creditors' voluntary liquidator appointed on 2 April 2013. The estimated deficiency to investors and creditors was £2,667,085
- Jarvis Porter Group plc - Administration completed 28 August 2008 - a dividend of 3 pence per share was paid to unsecured creditors
- United Industries plc - resigned 28 October 2005 - Administration completed 26 January 2008. The estimated deficiency to investors and creditors was £48,142,869
- Versatile Group Limited - Administrative receiver appointed 3 September 1998 by Bank of Scotland who had charges and cross guarantees supporting a debt of £2.4 million. In addition, the group had estimated deficiencies as regards creditors of £0.6 million and total estimated deficiencies in excess of £0.7 million. Versatile Group Limited was struck off the register on 15 May 2001

Administration ongoing:

- W.G. Mitchell (2005) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009
- W.G. Mitchell (Charlotte Square) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009
- W.G. Mitchell (George Street) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009
- W.G. Mitchell (Enterprises) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009
- W.G. Mitchell (Fifteen) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009
- W.G. Mitchell (Seven) Limited - Christopher Mills resigned on 12 January 2015 - Administrator appointed 1 April 2009

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

For further information:

Quantum Pharma Plc  
Chris Rigg, CEO & CFO  
Craig Swinhoe, Group Strategic Projects  
Director and Company Secretary

Tel: +44 (0) 1207 279 404

[www.quantumpharmapl.com](http://www.quantumpharmapl.com)

Zeus Capital Limited  
(Nominated Adviser & Joint Broker)

Tel: +44 (0) 20 3829  
5000

[www.zeuscapital.co.uk](http://www.zeuscapital.co.uk)

Andrew Jones / Nick Cowles / Jamie Peel  
Dominic Wilson / Adam Pollock / John Goold

N+1 Singer  
(Joint Broker)  
Aubrey Powell / James White / Sandy Ritchie  
Nick Owen / Brough Ransom

Tel: +44 (0) 20 7496  
3000

[www.n1singer.com](http://www.n1singer.com)

Media enquiries:  
Buchanan

Henry Harrison-Topham / Sophie Cowles / Steph Watson

Tel: +44 (0) 20 7466  
5000

[quantumpharma@buchanan.uk.com](mailto:quantumpharma@buchanan.uk.com) [www.buchanan.uk.com](http://www.buchanan.uk.com)

Notes to Editors

**Quantum Pharma Plc** is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through **three** divisions, offering a portfolio of innovative and complementary products and services.

**Specials** comprises four business units (*Quantum Pharmaceutical, UL Medicines, NuPharm and*

*Quantum Aseptics Services*), which manufacture, procure and supply unlicensed medicines (specials) and special obtains. In response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment, the division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products. With an expansive portfolio of products, Quantum is a trusted partner to the majority of large retail pharmacy chains in the UK, as well as pharmaceutical wholesalers, hospitals, independent pharmacies and dispensing doctors. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

**Niche Pharmaceuticals** comprises three business units (*Colonis, Lamda and PERN Consumer Products*) which develop and commercialise niche pharmaceuticals. This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed (special) status to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

**Medication Adherence** comprises two business units (*Biodose®* and *Biodose Services®*) which provide products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies across the UK and provides the Group with exposure to the homecare and supported living sectors of the care pathway complementing the focus of the remainder of the Group.

For further information, please visit [www.quantumpharmapl.com](http://www.quantumpharmapl.com).

This information is provided by RNS  
The company news service from the London Stock Exchange

END

MSCUKSNRNNARAAA